The First Clinical College, Gannan Medical University, Ganzhou 341000, China.
Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Curr Oncol. 2022 Oct 27;29(11):8133-8145. doi: 10.3390/curroncol29110642.
CD36 is a transmembrane glycoprotein that binds to a wide range of ligands, including fatty acids (FAs), cholesterol, thrombospondin-1 (TSP-1) and thrombospondin-2 (TSP-2), and plays an important role in lipid metabolism, immune response, and angiogenesis. Recent studies have highlighted the role of CD36 in mediating lipid uptake by tumor-associated immune cells and in promoting tumor cell progression. In cancer-associated fibroblasts (CAFs), CD36 regulates lipid uptake and matrix protein production to promote tumor proliferation. In addition, CD36 can promote tumor cell adhesion to the extracellular matrix (ECM) and induce epithelial mesenchymal transition (EMT). In terms of tumor angiogenesis, CD36 binding to TSP-1 and TSP-2 can both inhibit tumor angiogenesis and promote tumor migration and invasion. CD36 can promote tumor angiogenesis through vascular mimicry (VM). Overall, we found that CD36 exhibits diverse functions in tumors. Here, we summarize the recent research findings highlighting the novel roles of CD36 in the context of tumors.
CD36 是一种跨膜糖蛋白,可与多种配体结合,包括脂肪酸 (FAs)、胆固醇、血小板反应蛋白-1 (TSP-1) 和血小板反应蛋白-2 (TSP-2),在脂质代谢、免疫反应和血管生成中发挥重要作用。最近的研究强调了 CD36 在介导肿瘤相关免疫细胞摄取脂质以及促进肿瘤细胞进展中的作用。在癌相关成纤维细胞 (CAFs) 中,CD36 调节脂质摄取和基质蛋白的产生,以促进肿瘤增殖。此外,CD36 可以促进肿瘤细胞与细胞外基质 (ECM) 的黏附,并诱导上皮间质转化 (EMT)。在肿瘤血管生成方面,CD36 与 TSP-1 和 TSP-2 的结合均可抑制肿瘤血管生成,并促进肿瘤迁移和侵袭。CD36 可以通过血管拟态 (VM) 促进肿瘤血管生成。总的来说,我们发现 CD36 在肿瘤中表现出多种功能。在这里,我们总结了最近的研究结果,强调了 CD36 在肿瘤背景下的新作用。
Curr Oncol. 2022-10-27
Curr Pharm Des. 2007
Int J Mol Sci. 2022-1-6
Theranostics. 2019-7-9
J Cell Biol. 1997-8-11
Front Biosci. 2003-9-1
Genes (Basel). 2025-6-13
PLoS Comput Biol. 2025-5-7
BMC Womens Health. 2025-4-11
Cancer Drug Resist. 2025-2-8
Front Endocrinol (Lausanne). 2024
Biomolecules. 2024-7-11
J Cell Mol Med. 2024-5
Cancers (Basel). 2024-3-28